Abarceo is a preclinical stage company. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Medeon Science Park, Inkubatorn, Per Albin Hanssons Väg 41,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.abarceo.com
- Keywords
- beta cell dysfunction, VDAC-1, drug development, drug discovery, Alzheimer's, Mitochondria, Type 1 Diabetes.
- HQ
- Malmö, Sweden
Abarceo Pharma Ab Questions
Abarceo Pharma Ab's website is http://www.abarceo.com
Abarceo Pharma Ab's LinkedIn profile is https://se.linkedin.com/company/abarceopharmaab
Abarceo Pharma Ab has
9 employees.
View email and phone details for 9
employees at Abarceo Pharma Ab.
Abarceo Pharma Ab's industry is
Biotechnology Research
Abarceo Pharma Ab's top competitors are
Annexin Pharmaceuticals Ab (Publ),
Bioinvent International Ab,
Zerion Pharma,
Imvi Labs,
Akylox Therapeutics,
Elypta,
Medbeat,
2a Pharma,
Tikomed Ab,
Magle Chemoswed.
Abarceo Pharma Ab's categories are Biotechnology Research
Abarceo Pharma Ab's founding year is 2017
